| Trinh Thu Weatherly, CRNA | |
|
4500 13th St, Gulfport, MS 39501-2569 | |
| (228) 867-4000 | |
| Not Available |
| Full Name | Trinh Thu Weatherly |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 5 Years |
| Location | 4500 13th St, Gulfport, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083265185 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 901590 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Singing River Health System | Pascagoula, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hogan Surgical Center Pa | 4880791490 | 7 |
| Jackson County Anesthesia | 9931292729 | 40 |
| Singing River Health System | 3870405194 | 156 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
The dangers of heat were today highlighted by the Chief Medical Officer Sir Liam Donaldson with the publication of an updated heatwave plan and new public information leaflets.
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
Today's early morning highlights from the major news organizations include reports on Medicare ratings of nursing homes, the growing demand for home-health aides and accounts of the Obama administration's new contraception coverage rules.
› Verified 7 days ago
| Entity Name | Singing River Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083893937 PECOS PAC ID: 3870405194 Enrollment ID: O20031104000435 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
The dangers of heat were today highlighted by the Chief Medical Officer Sir Liam Donaldson with the publication of an updated heatwave plan and new public information leaflets.
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
Today's early morning highlights from the major news organizations include reports on Medicare ratings of nursing homes, the growing demand for home-health aides and accounts of the Obama administration's new contraception coverage rules.
› Verified 7 days ago
| Entity Name | Hogan Surgical Center Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104829597 PECOS PAC ID: 4880791490 Enrollment ID: O20070618000014 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
The dangers of heat were today highlighted by the Chief Medical Officer Sir Liam Donaldson with the publication of an updated heatwave plan and new public information leaflets.
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
Today's early morning highlights from the major news organizations include reports on Medicare ratings of nursing homes, the growing demand for home-health aides and accounts of the Obama administration's new contraception coverage rules.
› Verified 7 days ago
| Entity Name | Jackson County Anesthesia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922159219 PECOS PAC ID: 9931292729 Enrollment ID: O20070913000898 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
The dangers of heat were today highlighted by the Chief Medical Officer Sir Liam Donaldson with the publication of an updated heatwave plan and new public information leaflets.
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
Today's early morning highlights from the major news organizations include reports on Medicare ratings of nursing homes, the growing demand for home-health aides and accounts of the Obama administration's new contraception coverage rules.
› Verified 7 days ago
| Entity Name | Singing River Gulfport |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861010159 PECOS PAC ID: 5294154829 Enrollment ID: O20201001001497 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
The dangers of heat were today highlighted by the Chief Medical Officer Sir Liam Donaldson with the publication of an updated heatwave plan and new public information leaflets.
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
Today's early morning highlights from the major news organizations include reports on Medicare ratings of nursing homes, the growing demand for home-health aides and accounts of the Obama administration's new contraception coverage rules.
› Verified 7 days ago
| Entity Name | Singing River Health System |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1740918937 PECOS PAC ID: 3870405194 Enrollment ID: O20221202000423 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
The dangers of heat were today highlighted by the Chief Medical Officer Sir Liam Donaldson with the publication of an updated heatwave plan and new public information leaflets.
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
Today's early morning highlights from the major news organizations include reports on Medicare ratings of nursing homes, the growing demand for home-health aides and accounts of the Obama administration's new contraception coverage rules.
› Verified 7 days ago
| Entity Name | Singing River Gulfport |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1780312504 PECOS PAC ID: 5294154829 Enrollment ID: O20230106000462 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
The dangers of heat were today highlighted by the Chief Medical Officer Sir Liam Donaldson with the publication of an updated heatwave plan and new public information leaflets.
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
Today's early morning highlights from the major news organizations include reports on Medicare ratings of nursing homes, the growing demand for home-health aides and accounts of the Obama administration's new contraception coverage rules.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Trinh Thu Weatherly, CRNA 4500 13th St, Gulfport, MS 39501-2515 Ph: (228) 867-4000 | Trinh Thu Weatherly, CRNA 4500 13th St, Gulfport, MS 39501-2569 Ph: (228) 867-4000 |
News Archive
Ligon Discovery announced today that it has entered into a collaboration agreement with Lycera Corporation to apply its Small Molecule Microarray (SMM) screening technology to identify first-in-class drug candidates for immune disorders. Ligon will apply its SMM technology to screen protein targets identified by Lycera as critical to the development of certain immune disorders. Financial terms were not disclosed.
The dangers of heat were today highlighted by the Chief Medical Officer Sir Liam Donaldson with the publication of an updated heatwave plan and new public information leaflets.
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
Today's early morning highlights from the major news organizations include reports on Medicare ratings of nursing homes, the growing demand for home-health aides and accounts of the Obama administration's new contraception coverage rules.
› Verified 7 days ago
Kathryn Pittman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 15200 Community Rd, Gulfport, MS 39503 Phone: 228-575-7000 | |
Jason Wells, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4500 13th St, Gulfport, MS 39501 Phone: 228-865-3281 Fax: 228-867-5117 | |
Victor P Polito, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 15190 Community Rd, Suite 230a, Gulfport, MS 39503 Phone: 228-831-0204 Fax: 228-831-1868 | |
Glen Deitrick, C.R.N.A Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 15190 Community Rd, Suite 230a, Gulfport, MS 39503 Phone: 228-831-0204 Fax: 228-831-1868 | |
Glen Michael Cavalier, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 15200 Community Rd, Gulfport, MS 39503 Phone: 228-575-7000 | |
Julie K Klester, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 15190 Community Rd, Suite 230a, Gulfport, MS 39503 Phone: 228-831-0204 Fax: 228-831-1868 |